Carcinoma, Non-Small-Cell Lung Clinical Trials in Mineola, New York

3 studies are recruiting for carcinoma, non-small-cell lung in Mineola, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

    The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including f…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola, New York
    Locations
    418 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06119581 on ClinicalTrials.gov

  2. A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

    The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NYU Langone Health - Long Island, Mineola, New York
    Locations
    24 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06400472 on ClinicalTrials.gov

  3. A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola, New York
    Locations
    203 in total
    Run by
    Janssen Research & Development, LLC

    See if you can join NCT06667076 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.